Nature publishes the result of a study on a myocardial infarction treatment using iPS cells
With the goal of developing a new treatment for myocardial infarction, Ina Research has been pursuing a joint research project with a research team led by Associate Professor Yuji Shiba of the Institute for Biomedical Sciences (Director: Naoto Saito), Interdisciplinary Cluster for Cutting Edge Research at Shinshu University (hereinafter referred to as the “Shiba research team”) (as reported in a press release dated August 17, 2015). Today, I am pleased to inform you that the project’s achievements have been recognized and an article written by Associate Professor Yuji Shiba as lead author, and an employee of Ina Research as coauthor, will be published in the British multidisciplinary scientific journal Nature
Ina Research, Japan SLC, and DNA Link join forces for the effective use of PDX mouse models
Ina Research, Japan SLC, and DNA Link join forces for the effective use of PDX mouse modelsFirst-ever production and commercial use in Japan July 2018, Ina Research, Japan SLC, and Korea’s DNA Link launched a joint project for the effective use of “PDX (Patient derived xenograft) mouse models,” in which patient-derived cancer cells are transplanted into the living body of a mouse for the development of pharmaceutical products. Japan SLC, a provider of laboratory animals, will produce PDX models using cancer cells of Asian patients provided by DNA Link, which owns the library of human cancer cells.Ina Research will then use the optimal PDX model to conduct drug efficacy tests
Shinanomainichi news posted about new research project for CAR-T cell therapy.
Shinshu University establishes a domestic base in Ina toward the practical application of new cancer treatment “CAR-T cell therapy” Shinano Mainichi News as of September 21, 2018 Translated by Ina Research Shinshu University (headquartered in Matsumoto City) will establish a “Gene/Cell Therapy Research and Development Center” (tentative name), a facility for safety studies of “CAR-T cell therapy,” a new immune cell therapy for cancer, at Ina Research Inc. (Ina City) according to a source on September 20. The center will also provide services including safety studies of medical products. The center is planned to become fully operational in fiscal 2019. It was initiated as a government-commissioned project aimed at improving